At day 56, a significant increase in Lecithin–cholesterol acyltransferase (LCAT) concentration was detected in SLE subjects on tofacitinib that were STAT4 risk allele-positive (P = 0.024, 95% CI: 1.1–26.5) compared to the STAT4 risk allele-positive group on placebo or in subjects negative for this risk allele on tofacitinib (P = 0.04, 95% CI: −18.2, 10.2) (Fig. 3b). The gene discussed is STAT4; the disease is systemic lupus erythematosus.